Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings
- 19 March 2013
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 20 (1), 47-50
- https://doi.org/10.1177/1078155213476723
Abstract
Purpose To assess cost savings incurred with a dose rounding process that was implemented for ipilimumab. Secondarily, to assess response rates, patient tolerance, and adverse effects associated with ipilimumab upon implementation of dose rounding. Methods All patients with a diagnosis of metastatic melanoma and who received at least one dose ipilimumab were included for analysis. Doses of ipilimumab were calculated based upon the actual body weight (in kg) of the patient at the FDA approved regimen of 3 mg/kg every 21 days × 4 doses. The exact total mg dose was then rounded to the nearest 50 mg vial size. The potential effect on cost was calculated in US dollars for both the calculated and rounded doses. Waste, in mg, was defined as the amount of drug that may have been discarded if the calculated dose was used for therapy. The acquisition cost applied was US$120 per mg. Results 22 patients have received at least one dose of ipilimumab. 11 patients have completed therapy and received all four induction doses. 9 patients discontinued therapy early and 2 patients were still actively receiving induction at the time of this analysis. A total of 63 doses were given. The maximum potential cost savings by giving ipilimumab to the nearest 50 mg over the period was 155,400. Conclusions Dose rounding of ipilimumab to the nearest 50 mg has the potential to result in a significant cost savings by eliminating drug waste.Keywords
This publication has 12 references indexed in Scilit:
- Management of Immune-Related Adverse Events and Kinetics of Response With IpilimumabJournal of Clinical Oncology, 2012
- A new era for castrate resistant prostate cancer: A treatment review and updateJournal of Oncology Pharmacy Practice, 2012
- Delivering affordable cancer care in high-income countriesThe Lancet Oncology, 2011
- Automated Dose-Rounding Recommendations for Pediatric MedicationsPediatrics, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Cost savings from dose rounding of biologic anticancer agents in adultsJournal of Oncology Pharmacy Practice, 2010
- Dose-rounding of adjuvant chemotherapy for breast cancer: an audit of toxicityJournal of Oncology Pharmacy Practice, 2009
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- Drug waste minimisation and cost-containment in Medical Oncology: Two-year results of a feasibility studyBMC Health Services Research, 2008
- Practitioners? sources of clinical information on complementary and alternative medicine in oncologySupportive Care in Cancer, 2004